PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW176167View Pathway |
Zaleplon Predicted Metabolism Pathway newHomo sapiens
Metabolites of Zaleplon are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:28 Last Updated: November 29, 2023 at 14:28 |
PW127615View Pathway |
drug action
Zanamivir Action PathwayHomo sapiens
Zanamivir, also known as Relenza, is an inhibitor of the viral neuraminidase protein. This antiviral is used to treat and prevent influenza A and B infections. By interacting with the neuraminidase, Zabamivir renders the influenza virus unable to escape its host cell. Neuraminidases are essential for the cleaving of the terminal sialic acids on the glycosylated HA during the virus budding to facilitate its release. In consequence, the virus will not be able to infect other cells. This molecule is available as an intravenous solution or as a powder for inhalation.
|
Creator: Daphnee Created On: May 15, 2023 at 15:09 Last Updated: May 15, 2023 at 15:09 |
PW144675View Pathway |
drug action
Zanamivir Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:11 Last Updated: October 07, 2023 at 14:11 |
PW132540View Pathway |
Zanubrutinib Drug MetabolismHomo sapiens
Zanubrutinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zanubrutinib passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 22:20 Last Updated: September 21, 2023 at 22:20 |
PW146905View Pathway |
drug action
Zanubrutinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:19 Last Updated: October 07, 2023 at 19:19 |
PW124096View Pathway |
Zeatin BiosynthesisArabidopsis thaliana
Zeatin encourages lateral bud growth, resulting in bushier plants. It stimulates cell division when sprayed on meristems. Terpenoid backbone biosynthesis produces dimethylallyl diphosphate which, with different reactants, can result in different products with a byproduct of diphosphate. When reacted with tRNA adenine via tRNA dimethylallyltransferase, it results in the formation of tRNA containing 6-isopentenyl adenosine. When reacted via adenylate isopentenyltransferase 1, chloroplastic with either ATP, ADP, or AMP, it results in the formation of the corresponding isopentenyl, which in turn reacts with oxygen and reduced NADPH hemoprotein reductase via cytokinin hydroxylase, resulting in the formation of trans-zeatin riboside with the corresponding phosphates and byproducts of water and oxidized NADPH hemoprotein reductase.
|
Creator: Jeanne Coleongco Created On: August 20, 2020 at 11:09 Last Updated: August 20, 2020 at 11:09 |
PW012895View Pathway |
Zeaxanthin BiosynthesisArabidopsis thaliana
Zeaxanthin biosynthesis is a pathway that occurs in the chloroplast by which lycopene becomes zeaxanthin, one of the most common carotenoid alcohols found in nature . The first two reactions are catalyzed by lycopene beta cyclase which uses NAD(P)H as a cofactor to convert lycopene into gamma-carotene and gamma-carotene into beta-carotene. The last two reactions are catalyzed by beta-carotene 3-hydroxylase which uses ferredoxin and Fe2+ as cofactors to convert beta-carotene into beta-cryptoxanthin and beta-cryptoxanthin into zeaxanthin.
|
Creator: Carin Li Created On: February 23, 2017 at 01:47 Last Updated: February 23, 2017 at 01:47 |
PW132554View Pathway |
Zeaxanthin Drug MetabolismHomo sapiens
Zeaxanthin is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zeaxanthin passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 22:24 Last Updated: September 21, 2023 at 22:24 |
PW146281View Pathway |
drug action
Zeaxanthin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:51 Last Updated: October 07, 2023 at 17:51 |
PW127262View Pathway |
disease
Zellweger SyndromeHomo sapiens
Zellweger syndrome, also known as cerebrohepatorenal syndrome, is an autosomal recessive peroxisome biogenesis disorder that is part of the family of Zellweger spectrum disorders. It is caused by a defect in one of 12 or more of the PEX genes (PEX1, 2, 3, 5, 6, 10, 12, 13, 14, 16, 19 and 26) that produce proteins called peroxins. Peroxins are used in the formation of peroxisomes, and can be involved in recognition of proteins targeted for the peroxisome, as well as their transport into the peroxisome. Peroxisomes typically break down both very long chain and branched fatty acids, but if they aren't present, these fatty acids build up in the blood and body, harming organs such as the brain and liver. Additionally, due to the fact that some processes, such as plasmalogen biosynthesis, occur in or using peroxisomes, and can lead to deficiencies in plasmalogens. These are important in brain and lung function, leading to other symptoms. Zellweger syndrome is characterized by an increase in levels of very long chain fatty acids in the blood plasma, as well as more visible physical symptoms, such as an abnormally large or small head at birth, characteristic facial features and poor muscle tone, which can lead to an inability of infants to feed. Other symptoms include an enlarged liver, skeletal abnormalities and low CNS function. Infants very rarely live longer than one year, and the only treatment is for symptoms the patient is experiencing, not for the syndrome itself.
|
Creator: Ray Kruger Created On: November 24, 2022 at 11:22 Last Updated: November 24, 2022 at 11:22 |